Inhibikase Therapeutics Soars 6.79% on Russell 2000 Index Addition

Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) surged 6.79% in pre-market trading on June 30, 2025, marking a significant rise in its stock price.

Inhibikase Therapeutics, Inc. has been added to the Russell 2000 Index, a move that is likely to increase its visibility and attract more investors. The company is currently rated as a "BUY" by analysts, with an average target price that suggests further upside potential.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's disease and related disorders. This specialized focus positions the company well within the biotechnology sector, where innovative treatments for neurological conditions are in high demand.